{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:27Z","timestamp":1790191947723,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jfma.2020.08.021","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T16:53:02Z","timestamp":1598719982000},"page":"863-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"120","author":[{"given":"Cih-En","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Yi","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chian-Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hua","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tsung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-7229","authenticated-orcid":false,"given":"Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jfma.2020.08.021_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.021_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematol Am Soc Hematol Edu Program"},{"issue":"22","key":"10.1016\/j.jfma.2020.08.021_bib3","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2020.08.021_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.021_bib5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jfma.2020.08.021_bib6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.021_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.16174","article-title":"A journey through infectious risk associated with ruxolitinib","volume":"187","author":"Sant'Antonio","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.021_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jfma.2020.08.021_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.021_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-019-00527-7","article-title":"The Rationale for immunotherapy in myeloproliferative neoplasms","volume":"14","author":"Masarova","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.021_bib11","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jfma.2020.08.021_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3324\/haematol.2016.154385","article-title":"Aberrant let7a\/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms","volume":"102","author":"Chen","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.021_bib13","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.3324\/haematol.2018.187989","article-title":"Quantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of JAK2V617F mutant allele burdens","volume":"103","author":"Hsu","year":"2018","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.jfma.2020.08.021_bib14","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.jfma.2020.08.021_bib15","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.021_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jfma.2020.08.021_bib17","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2017-11-737411","article-title":"Hepcidin agonists as therapeutic tools","volume":"131","author":"Casu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2020.08.021_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","article-title":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","volume":"56","author":"Verstovsek","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.021_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jfma.2020.08.021_bib20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/leu.2008.41","article-title":"Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals","volume":"22","author":"Muller","year":"2008","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.jfma.2020.08.021_bib21","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jfma.2020.08.021_bib22","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1634\/theoncologist.2018-0747","article-title":"Accelerated Risk of Premature Ischemic Stroke in 5-Year Survivors of Nasopharyngeal Carcinoma","volume":"24","author":"Chen","year":"2019","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.jfma.2020.08.021_bib23","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.021_bib24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.021_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-008-0498-4","article-title":"Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera","volume":"87","author":"Larsen","year":"2008","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jfma.2020.08.021_bib26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.jfma.2020.08.021_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jfma.2020.08.021_bib28","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jfma.2020.08.021_bib29","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.jfma.2020.08.021_bib30","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.021_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/onc.2011.221","article-title":"Inflammatory signaling compromises cell responses to interferon alpha","volume":"31","author":"Huangfu","year":"2012","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.jfma.2020.08.021_bib32","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jfma.2020.08.021_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2014.04.005","article-title":"Anemia of inflammation","volume":"28","author":"Nemeth","year":"2014","journal-title":"Hematol Oncol Clin N Am"},{"issue":"14","key":"10.1016\/j.jfma.2020.08.021_bib34","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jfma.2020.08.021_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620303958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620303958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:44:11Z","timestamp":1760539451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620303958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0929664620303958"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.021","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}